Baloxavir Marboxil Polymorphs: Investigating the Influence of Molecule Packing on the Dissolution Behavior

Baloxavir marboxil (BXM) is a new blockbuster FDA-approved anti-influenza virus agent. However, its poor solubility has limited its oral bioavailability. In this study, BXM was crystallized from several organic solvents, obtaining three polymorphs, and their dissolution behaviors were studied. Detailed crystallographic examination revealed that Form I is monoclinic, space group P2(1), with unit cell parameters a = 7.1159 (3) angstrom, b = 20.1967 (8) angstrom, c = 9.4878 (4) angstrom, beta = 109.033 (1)degrees, V = 1289.02 (9) angstrom(3), and Z = 2, and Form II is monoclinic, space group P2(1), with unit cell parameters a = 7.1002 (14) angstrom, b = 39.310 (7) angstrom, c = 9.7808 (18) angstrom, beta = 110.966 (5)degrees, V = 2549.2 (8) angstrom(3), and Z = 4. Form I has a rectangular three-dimensional energy frameworks net, while Form II has a two-dimensional net. On the other hand, Form II has a much larger percentage of its surface area of exposed hydrogen bond acceptors than Form I. These crystallographic features offered increased solubility and dissolution rate to Form II. The results of stability and solubility experiments suggest that Form II may be preferred in the solid form used for the industrial preparation of BXM medicinal products.